Toronto, Ontario – (December 21, 2022) – Therma Bright Inc. (TSXV:THRM) (OTCQB:TBRIF) developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide a summary of activities and accomplishments achieved during 2022 as outlined below.
One of the companies to have come into focus among investors in the medical devices industry in recent times is Therma Bright Inc. The company is well-known for having developed the AcuVid™ COVID-19 Rapid Antigen Saliva Test and other devices.
Yesterday, it came into focus among investors after it announced updates for the end of 2022. The company noted that it had been getting feedback from the regulator Health Canada with regards to the AcuVid product and the submission had been progressing through the strident approval process.
On the other hand, due to the changes in the market and in the processes of the United States Food and Drug Administration the company was still in the process of exploring its options for the United States regulatory process.
At this point in time, Therma Bright is considering a range of options in order to make it in the lucrative United States market. One of the options that is being considered by the company is that of sending in a breakthrough designation application to the regulatory authorities.
The company also announced in its update yesterday that it already possesses an EU-CE mark for the product in the European Union market. Another important update was with regard to the Venowave product. Therma Bright noted that the product had been sold in the United States previously and had been reimbursed through Medicaid and Medicare. In 2022, the company applied for more reimbursement codes so that the process could be made easier for healthcare providers and patients.